{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:51:09Z","timestamp":1791298269295,"version":"4.1.0"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,5,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non\u2014small-cell lung cancer (NSCLC) previously treated with chemotherapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg\/m<jats:sup>2<\/jats:sup> intravenously (IV) day 1 with vitamin B<jats:sub>12<\/jats:sub>, folic acid, and dexamethasone or docetaxel 75 mg\/m<jats:sup>2<\/jats:sup> IV day 1 with dexamethasone every 21 days. The primary end point was overall survival. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Five hundred seventy-one patients were randomly assigned. Overall response rates were 9.1% and 8.8% (analysis of variance P = .105) for pemetrexed and docetaxel, respectively. Median progression-free survival was 2.9 months for each arm, and median survival time was 8.3 versus 7.9 months (P = not significant) for pemetrexed and docetaxel, respectively. The 1-year survival rate for each arm was 29.7%. Patients receiving docetaxel were more likely to have grade 3 or 4 neutropenia (40.2% v 5.3%; P &lt; .001), febrile neutropenia (12.7% v 1.9%; P &lt; .001), neutropenia with infections (3.3% v 0.0%; P = .004), hospitalizations for neutropenic fever (13.4% v 1.5%; P &lt; .001), hospitalizations due to other drug related adverse events (10.5% v 6.4%; P = .092), use of granulocyte colony-stimulating factor support (19.2% v 2.6%, P &lt; .001) and all grade alopecia (37.7% v 6.4%; P &lt; .001) compared with patients receiving pemetrexed. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-line NSCLC when available. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.08.163","type":"journal-article","created":{"date-parts":[[2004,4,29]],"date-time":"2004-04-29T22:34:18Z","timestamp":1083278058000},"page":"1589-1597","source":"Crossref","is-referenced-by-count":2013,"title":["Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non\u2013Small-Cell Lung Cancer Previously Treated With Chemotherapy"],"prefix":"10.1200","volume":"22","author":[{"given":"Nasser","family":"Hanna","sequence":"first","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank V.","family":"Fossella","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Pereira","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"De Marinis","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"von Pawel","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Gatzemeier","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Chang Yao","family":"Tsao","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Pless","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Muller","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Liang","family":"Lim","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Desch","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Szondy","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radj","family":"Gervais","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shaharyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Manegold","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Paul","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Paoletti","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Einhorn","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Paul A.","family":"Bunn","sequence":"additional","affiliation":[{"name":"From Indiana University and the Hoosier Oncology Group; Eli Lilly and Company, Indianapolis, IN; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Denver, CO; Virginia Cancer Institute, Richmond, VA; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Instituto Arnaldo Vieira de Carvalho, Sao Paolo, Brazil; San Camillo-Forlanini Hospitals, Rome, Italy; Chang Gung Memorial Hospital, Taoyuan, Taiwan; University Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Parkin DM, Bray FI, Devessa SS: Cancer burden for the year 2000: The global picture. Eur J Cancer 37:S4,2001-S66,  (suppl 8)","DOI":"10.1016\/S0959-8049(01)00267-2"},{"key":"R2","unstructured":"Stephens R, Fairlamb D, Gower N, et al: The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC): Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21:291a,2002,  (abstr 1161)"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7010.899"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1866"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2095"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2354"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Clarke S, Boyer M, Millward M, et al: Phase II study of LY231514, a multi-targeted antifolate, in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:465a,1997,  (abstr 1670)","DOI":"10.1016\/S0169-5002(97)89313-0"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1194"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg099"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"R11","unstructured":"Bunn P, Paoletti P, Niyikiza C, et al: Vitamin B12 and folate reduce toxicity of Alimta (Pemetrexed Disodium, LY231514, MTA) a novel antifolate\/antimetabolite. Proc Am Soc Clin Oncol 20:76a,2001,  (abstr 300)"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2003.s.006"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-X"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1400"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Leemis LM, Trivedi KS: A comparison of approximate interval estimators for the Bernoulli parameter. Am Stat 50:63,1996-68,","DOI":"10.1080\/00031305.1996.10473544"},{"key":"R16","unstructured":"Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719,1959-748,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1007\/BF00944177"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"}],"updated-by":[{"DOI":"10.1200\/jco.22.02546","type":"new_edition","label":"New edition","source":"publisher","updated":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.08.163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:29:14Z","timestamp":1653510554000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.08.163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,5,1]]}},"alternative-id":["10.1200\/JCO.2004.08.163"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.08.163","relation":{"new_edition":[{"id-type":"doi","id":"10.1200\/JCO.22.02546","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}